- Home
- NTRA
NTRA
Natera Inc.
as 05-08-2025 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 20.9B | IPO Year: | 2015 |
| Target Price: | $176.65 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $92.14 - $183.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,696,911,000 | Revenue Growth: | 56.75% |
| Revenue Growth (this year): | 15.45% | Revenue Growth (next year): | 18.43% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | May 1 '25 | Sell | $150.39 | 3,000 | $450,353.06 | 136,205 | |
| Marcus Gail Boxer | NTRA | Director | May 1 '25 | Sell | $149.99 | 4,000 | $606,432.75 | 13,673 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Apr 28 '25 | Sell | $152.18 | 2,206 | $335,714.37 | 136,205 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Apr 28 '25 | Sell | $152.18 | 1,993 | $303,299.52 | 223,674 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Apr 28 '25 | Sell | $152.18 | 1,709 | $260,079.72 | 155,237 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Apr 28 '25 | Sell | $153.84 | 5,063 | $776,587.66 | 73,539 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Apr 28 '25 | Sell | $152.18 | 1,718 | $261,449.36 | 2,362,570 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Apr 28 '25 | Sell | $152.18 | 6,203 | $943,987.43 | 192,162 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Apr 22 '25 | Sell | $149.06 | 2,161 | $321,809.13 | 73,539 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Apr 21 '25 | Sell | $146.20 | 296 | $43,085.08 | 136,205 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings
Business Wire
2 days ago
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
StockStory
2 days ago
What To Expect From Natera’s (NTRA) Q1 Earnings
Medical Device Network
3 days ago
Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas
Business Wire
4 days ago
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
Business Wire
8 days ago
Natera to Report its First Quarter Results on May 8, 2025
Simply Wall St.
9 days ago
Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study
Business Wire
10 days ago
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.